SINOPEG signed a non-exclusive Licensing and Commercialization Agreement with QuiaPEG Pharmaceutical Holding AB in 2018 for the manufacturing, marketing and sales of products and services based on QuiaPEG´s proprietary Uni-Qleaver® technology. QuiaPEG is headquartered in Uppsala, Sweden, who develops proprietary, releasable PEGylation technologies (Uni-Qleaver®）for the development of prodrugs and biobetters with improved pharmacological properties, e.g. extended half-life and increased tolerability.

Welcome to the website:http://www.quiapeg.com/